Three phase 1/2, open-label studies of cereblon e3 ligase modulator (celmod)-based regimens in newly diagnosed (nd) or relapsed/refractory (r/r) non-hodgkin lymphoma (nhl)
Hematological Oncology（2021）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要